Comparison of Respiratory Syncytial Virus (RSV)-Specific Antibody Durability in Pregnant/Postpartum Individuals and Older Adults After RSV Vaccination.

Kachikis, Alisa; Frivold, Collrane; Pike, Mindy; Reed, Jonathan C; Stolarczuk, Jennifer E; McVey, Kittredge; Clark, Erica; Mauer, Clarice et al. · J Infect Dis · 2026

prospective_cohort · Level II

Where this comes from

Record sourced from PubMed, PMID 41885612.
Also identified by DOI 10.1093/infdis/jiag111.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

Respiratory syncytial virus (RSV) vaccination is recommended in pregnancy. Limited data exist regarding antibody (Ab) durability to inform revaccination timing. We conducted prospective cohort studies among pregnant and older adults after first RSV vaccination in 2023-2024. Longitudinal samples from 50 pregnant (36 vaccinated) and 16 vaccinated older adults were collected until 12-15 months after vaccination and tested for RSV binding and neutralizing Ab. Mean Ab levels 12-15 months after vaccination were similar between vaccinated maternal and older adult participants (P = .73), suggesting Ab durability up to 1 year after maternal RSV vaccination. RSV binding and neutralizing Ab titers were strongly correlated (R = .73).

Read the full text

View on PubMed · Publisher (DOI)